EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pharmacology of PACAP and VIP receptors in the spinal cord highlights the importance of the PAC 1 receptor

Zoe Tasma iD, Tayla A Rees, Song Guo, Sheryl Tan, Simon J O'Carroll, Richard L M Faull, Maurice A Curtis, Sarah L Christensen, Debbie L Hay iD, Christopher S Walker iD

British Journal of Pharmacology · 2024-08 · 181 (15) · 2655-2675

DOI: 10.1111/bph.16376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 14.04.2024. Verfasst von Zoe Tasma und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological Sciences, The University of Auckland, Auckland, New Zealand. Hauptthemen laut MEDLINE: Spinal Cord, Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I, Pituitary Adenylate Cyclase-Activating Polypeptide, Vasoactive Intestinal Peptide. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Royal Society Te Apārangi, Health Research Council of New Zealand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose The spinal cord is a key structure involved in the transmission and modulation of pain. Pituitary adenylate cyclase‐activating peptide (PACAP) and vasoactive intestinal peptide (VIP), are expressed in the spinal cord. These peptides activate G protein‐coupled receptors (PAC 1 , VPAC 1 and VPAC 2 ) that could provide targets for the development of novel pain treatments. However, it is not clear which of these receptors are expressed within the spinal cord and how these receptors signal. Experimental Approach Dissociated rat spinal cord cultures were used to examine agonist and antagonist receptor pharmacology. Signalling profiles were determined for five signalling pathways. The expression of different PACAP and VIP receptors was then investigated in mouse, rat and human spinal cords using immunoblotting and immunofluorescence. Key Results PACAP, but not VIP, potently stimulated cAMP, IP 1 accumulation and ERK and cAMP response element‐binding protein (CREB) but not Akt phosphorylation in spinal cord cultures. Signalling was antagonised by M65 and PACAP 6–38 . PACAP‐27 was more effectively antagonised than either PACAP‐38 or VIP. The patterns of PAC 1 and VPAC 2 receptor‐like immunoreactivity appeared to be distinct in the spinal cord. Conclusions and Implications The pharmacological profile in the spinal cord suggested that a PAC 1 receptor is the major functional receptor subtype present and thus likely mediates the nociceptive effects of the PACAP family of peptides in the spinal cord. However, the potential expression of both PAC 1 and VPAC 2 receptors in the spinal cord highlights that these receptors may play differential roles and are both possible therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spinal CordReceptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type IPituitary Adenylate Cyclase-Activating PolypeptideVasoactive Intestinal PeptideAnimalsHumansMiceRatsSignal TransductionReceptors, Vasoactive Intestinal PeptideCells, CulturedRats, Sprague-DawleyMaleMice, Inbred C57BLCyclic AMPReceptors, Vasoactive Intestinal Peptide, Type II

Stichwörter der Autor:innen

PAC1 receptorVPAC1 receptorVPAC2 receptorpituitary adenylate cyclase‐activating peptide (PACAP)spinal cordvasoactive intestinal peptide (VIP)

Substanzen

Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type IPituitary Adenylate Cyclase-Activating PolypeptideVasoactive Intestinal PeptideReceptors, Vasoactive Intestinal PeptideCyclic AMPReceptors, Vasoactive Intestinal Peptide, Type II

Autor:innen und Institutionen

  • School of Biological Sciences, The University of Auckland, Auckland, New Zealand.
  • Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand.
  • Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Department of Odontology, Panum Institute, Faculty of Health, University of Copenhagen, Copenhagen, Denmark.
  • Department of Anatomy and Medical Imaging and Centre for Brain Research, Faculty of Medical and Health Science, The University of Auckland, Auckland, New Zealand.
  • Department of Pharmacology and Toxicology, The University of Otago, Dunedin, New Zealand.

ORCID-Profile: Zoe Tasma, Debbie L Hay, Christopher S Walker

Förderung

  • Royal Society Te Apārangi
  • Health Research Council of New Zealand

Zitieren

APA

Tasma, Z., Rees, T. A., Guo, S., Tan, S., O'Carroll, S. J., Faull, R. L. M., Curtis, M. A., Christensen, S. L., Hay, D. L., & Walker, C. S. (2024). Pharmacology of PACAP and VIP receptors in the spinal cord highlights the importance of the PAC 1 receptor. British Journal of Pharmacology, 181(15), 2655-2675. https://doi.org/10.1111/bph.16376

Vancouver

Tasma Z, Rees TA, Guo S, Tan S, O'Carroll SJ, Faull RLM, et al. Pharmacology of PACAP and VIP receptors in the spinal cord highlights the importance of the PAC 1 receptor. British Journal of Pharmacology. 2024;181(15):2655-2675. doi:10.1111/bph.16376

BibTeX
@article{Tasma2024,
  author = {Tasma, Zoe and Rees, Tayla A and Guo, Song and Tan, Sheryl and O'Carroll, Simon J and Faull, Richard L M and Curtis, Maurice A and Christensen, Sarah L and Hay, Debbie L and Walker, Christopher S},
  title = {Pharmacology of PACAP and VIP receptors in the spinal cord highlights the importance of the PAC 1 receptor},
  journal = {British Journal of Pharmacology},
  year = {2024},
  volume = {181},
  number = {15},
  pages = {2655--2675},
  doi = {10.1111/bph.16376}
}
Kostenlos starten →